Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder. A Systematic Review Maya E. O’Neil, PhD; Shannon M. Nugent, PhD; Benjamin J. Morasco, PhD; Michele Freeman, MPH; Allison Low, BA; Karli Kondo, PhD; Bernadette Zakher, MBBS; Camille Elven, MD; Makalapua Motu’apuaka, BA; Robin Paynter, MLIS; and Devan Kansagara, MD, MCR Annals of Internal Medicine, 2020 doi : 10.7326/M17-0477 Background : Cannabis is available from medical dispensaries for treating posttraumatic stress disorder (PTSD) in many states of the union, yet its efficacy in treating PTSD symptoms remains uncertain. Purpose : To identify ongoing studies and review existing evidence regarding the benefits and harms of plant-based [...]
Lire la suitePharmacotherapy for the Treatment of Cannabis Use Disorder. A Systematic Review Karli K. Kondo, PhD; Benjamin J. Morasco, PhD; Shannon M. Nugent, PhD; Chelsea K. Ayers, MPH; Maya E. O’Neil, PhD; Michele Freeman, MPH, and Devan Kansagara, MD, MCR Annals of Internal Medicine, 2020, 172, 398-412. doi : 10.7326/M19-1105 Background : Cannabis use disorder (CUD) is a growing concern, and evidence-based data are needed to inform treatment options. Purpose : To review the benefits and risks of pharmacotherapies for the treatment of CUD. Data Sources : MEDLINE, PsycINFO, Cochrane Database of Systematic Reviews, and clinical trial registries from inception through September 2019. Study Selection : Pharmacotherapy trials [...]
Lire la suiteNeural Mechanisms for the Cannabinoid Modulation of Cognition and Affect in Man : A Critical Review of Neuroimaging Studies Sagnik Bhattacharyya, Zerrin Atakan, Rocio Martin-Santos, Jose A. Crippa and Philip K. McGuire Current Pharmaceutical Design, 2012, 18, 5045-5054 Abstract Pharmacological challenge in conjunction with neuroimaging techniques has been employed for over two decades now to understand the neural basis of the cognitive, emotional and symptomatic effects of the main ingredients of cannabis, the most widely used illicit drug in the world. This selective critical review focuses on the human neuroimaging studies investigating the effects of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), the two main cannabinoids [...]
Lire la suiteFrequent Cannabis Use in Depression Tripled Over Past Decade Batya Swift Yasgur, MA, LSW Medscape, August 19, 2020 Not only are individuals with depression at significantly higher risk for cannabis use compared with those without depression, this trend has increased dramatically over the last decade, new research shows. Investigators analyzed data from more than 16,000 US adults between the ages of 20 and 59 years and found that those with depression had almost twice the odds of any past-month cannabis use compared with those without depression. Odds rose from 1.5 in the 2005-2006 period to 2.3 in the 2015-2016 period. Moreover, the odds ratio (OR) [...]
Lire la suiteOral Cannabidiol Does Not Convert to Δ8-THC or Δ9-THC in Humans : A Pharmacokinetic Study in Healthy Subjects José Alexandre S. Crippa, Antonio Waldo Zuardi, Jaime Eduardo Cecílio Hallak, Bruna Miyazawa, Sandra Aparecido Bernardo, Carmem Maria Donaduzzi, Silvane Guzzi, Wagner Alex Jann Favreto, Alline Campos, Maria Eugênia C. Queiroz, Francisco S. Guimarães, Patrícia Moura da Rosa Zimmermann, Letícia Mello Rechia, Volnei Jose Tondo Filho Cannabis and Cannabinoid Research, 2020, Vol. 5, No. 1 Doi : 10.1089/can.2019.0024 Abstract Introduction: Recent studies have suggested that cannabidiol (CBD) could interconvert into Delta-8- and Delta-9- tetrahydrocannabinol. Materials and Methods: Thus, we tested the plasma samples of 120 healthy human subjects [...]
Lire la suiteFDA Okays New Indication for Esketamine Nasal Spray Megan Brooks Medscape - Aug 03, 2020. The US Food and Drug Administration (FDA) has approved the supplemental new drug application for esketamine nasal spray (Spravato, Janssen Pharmaceuticals) to treat depressive symptoms in adults with major depressive disorder (MDD) and acute suicidal ideation or behavior. The FDA approved esketamine nasal spray for treatment-resistant depression in March 2019, as reported by Medscape Medical News. The new indication is based on data from two identical phase 3 trials — ASPIRE I and ASPIRE II — which evaluated the efficacy and safety of the nasal spray in addition to a comprehensive standard of care [...]
Lire la suiteCannabidiol for the treatment of cannabis use disorder : a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial Tom P Freeman, Chandni Hindocha, Gianluca Baio, Natacha D C Shaban, Emily M Thomas, Danica Astbury, Abigail M Freeman, Rachel Lees, Sam Craft, Paul D Morrison, Michael A P Bloomfield, Dominic O'Ryan, Jane Kinghorn, Celia J A Morgan, Ali Mofeez, H Valerie Curran The Lancet Psychiatry, 2020, doi : 10.1016/S2215-0366(20)30290-X Abstract Background : A substantial and unmet clinical need exists for pharmacological treatment of cannabis use disorders. Cannabidiol could offer a novel treatment, but it is unclear which doses might be efficacious or safe. Therefore, we aimed to identify efficacious doses and eliminate inefficacious doses in a phase 2a trial using [...]
Lire la suiteCytotoxic Effects of Cannabinoids on Human HT-29 Colorectal Adenocarcinoma Cells : Different Mechanisms of THC, CBD, and CB83 Daniela Cerretani, Giulia Collodel, Antonella Brizzi, Anna Ida Fiaschi, Andrea Menchiari, Elena Moretti, Laura Moltoni, Lucia Micheli International Journal of Molecular Sciences, 2020, 21, 5533 Doi : 10.3390/ijms21155533 Abstract In this study, we investigated the effects of exposition to IC50 dose for 24 h of a new synthetic cannabinoid (CB83) and of phytocannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on HT-29 colorectal carcinoma cells. Cell viability and proliferative activity evaluated using the MTT, lactate dehydrogenase (LDH), and CyQUANT assays showed that cell viability was significantly affected when CB83, THC, and CBD [...]
Lire la suiteCannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in Cancer Uchini S. Kosgodage, Rhys Mould, Aine B. Henley, Alistair V. Nunn, Geoffrey W. Guy, E. L. Thomas, Jameel M. Inal, Jimmy D. Bell and Sigrun Lange Frontiers in Pharmacology, 2018, Volume 9, Article 889 doi : 10.3389/fphar.2018.00889 Exosomes and microvesicles (EMV) are lipid bilayer-enclosed structures, released by cells and involved in intercellular communication through transfer of proteins and genetic material. EMV release is also associated with various pathologies, including cancer, where increased EMV release is amongst other associated with chemo-resistance and active transfer of pro-oncogenic factors. Recent studies show that [...]
Lire la suiteIACM-Bulletin du 27 Juillet 2020 IACM: Possibilités sophistiquées de présenter des posters lors de la conférence virtuelle Science/Homme: Au Canada, environ 20% des patients souffrant d'arthrite et de douleurs musculaires consomment du cannabis et davantage aimeraient l'essayer Science: Le CBD et le CBG dans les bains de bouche sont aussi efficaces que la chlorhexidine Science/Homme: Le cannabis n'a aucun impact négatif sur la condition physique des personnes âgées En bref Un coup d'œil sur le passé IACM: Possibilités sophistiquées de présenter des posters lors de la conférence virtuelle La 11e Conférence IACM sur [...]
Lire la suite